Jamie C Harris1, Jeannine M Coburn2, Andre Kajdacsy-Balla3, David L Kaplan2, Bill Chiu4. 1. Department of Surgery, Rush University Medical Center, 1750 W. Harrison St, Suite 785, Chicago, IL, 60612, USA. 2. Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA, 02155, USA. 3. Division of Pathology, University of Illinois Chicago, 840 S. Wood St. Suite 130 CSN, Chicago, IL, 60612. 4. Department of Surgery, University of Illinois at Chicago, 840 S. Wood Street, Suite 416, Chicago, IL, 60612, USA. Electronic address: bchiumd@uic.edu.
Abstract
BACKGROUND: Sarcoma accounts for 20% of solid tumors in children. Surgery has significant morbidity. We hypothesized that delivering chemotherapy directly into tumors through sustained release silk systems could slow tumor growth. METHODS: Human Ewing sarcoma cells A673 were cultured with vincristine and doxorubicin to determine half maximal inhibitory concentration (IC50). Cells were injected into mouse hind leg to create orthotopic tumors. Tumor volumes were measured using ultrasound. When volume reached >250mm3, interventions included: implantation of drug-free silk foam (Control-F), doxorubicin 400μg foam (Dox400-F), vincristine 50μg foam (Vin50-F), drug-free silk gel (Control-G), vincristine 50μg gel (Vin50-G), or single dose intravenous vincristine 50μg (Vin50-IV). End-point was volume>1000mm3. Kaplan Meier and ANOVA were used. RESULTS: IC50 for vincristine and doxorubicin was 0.5ng/mL and 200ng/mL, respectively. There was no difference between Dox400-F [6±1days to end point (DTEP)] and Control-F (5±1.3 DTEP). Vin50-F (12.4±3.5 DTEP) had slower growth compared to Control-F (p<0.001), and there was no difference between Vin50-F and Vin50-IV (14±0 DTEP). Growth was slowest with Vin50-G, 28±10.3 DTEP compared to all other treatment groups (p<0.05). CONCLUSION: Sustained delivery of vincristine inside the sarcoma tumor with silk gel decreased tumor growth. Applying this intratumoral treatment strategy may potentially decrease the extent of surgical excision. Copyright Â
BACKGROUND:Sarcoma accounts for 20% of solid tumors in children. Surgery has significant morbidity. We hypothesized that delivering chemotherapy directly into tumors through sustained release silk systems could slow tumor growth. METHODS:HumanEwing sarcoma cells A673 were cultured with vincristine and doxorubicin to determine half maximal inhibitory concentration (IC50). Cells were injected into mouse hind leg to create orthotopic tumors. Tumor volumes were measured using ultrasound. When volume reached >250mm3, interventions included: implantation of drug-free silk foam (Control-F), doxorubicin 400μg foam (Dox400-F), vincristine 50μg foam (Vin50-F), drug-free silk gel (Control-G), vincristine 50μg gel (Vin50-G), or single dose intravenous vincristine 50μg (Vin50-IV). End-point was volume>1000mm3. Kaplan Meier and ANOVA were used. RESULTS: IC50 for vincristine and doxorubicin was 0.5ng/mL and 200ng/mL, respectively. There was no difference between Dox400-F [6±1days to end point (DTEP)] and Control-F (5±1.3 DTEP). Vin50-F (12.4±3.5 DTEP) had slower growth compared to Control-F (p<0.001), and there was no difference between Vin50-F and Vin50-IV (14±0 DTEP). Growth was slowest with Vin50-G, 28±10.3 DTEP compared to all other treatment groups (p<0.05). CONCLUSION: Sustained delivery of vincristine inside the sarcoma tumor with silk gel decreased tumor growth. Applying this intratumoral treatment strategy may potentially decrease the extent of surgical excision. Copyright Â
Authors: F Philipp Seib; Jeannine Coburn; Ilona Konrad; Nikolai Klebanov; Gregory T Jones; Brian Blackwood; Alain Charest; David L Kaplan; Bill Chiu Journal: Acta Biomater Date: 2015-04-08 Impact factor: 8.947
Authors: Trang H La; Paul A Meyers; Leonard H Wexler; Kaled M Alektiar; John H Healey; Michael P Laquaglia; Patrick J Boland; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-28 Impact factor: 7.038
Authors: Nathalie Gaspar; Douglas S Hawkins; Uta Dirksen; Ian J Lewis; Stefano Ferrari; Marie-Cecile Le Deley; Heinrich Kovar; Robert Grimer; Jeremy Whelan; Line Claude; Olivier Delattre; Michael Paulussen; Piero Picci; Kirsten Sundby Hall; Hendrik van den Berg; Ruth Ladenstein; Jean Michon; Lars Hjorth; Ian Judson; Roberto Luksch; Mark L Bernstein; Perrine Marec-Bérard; Bernadette Brennan; Alan W Craft; Richard B Womer; Heribert Juergens; Odile Oberlin Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: S S Donaldson; M Torrey; M P Link; A Glicksman; L Gilula; F Laurie; J Manning; J Neff; W Reinus; E Thompson; J J Shuster Journal: Int J Radiat Oncol Biol Phys Date: 1998-08-01 Impact factor: 7.038
Authors: Jasmine Zeki; Jordan S Taylor; Burcin Yavuz; Jeannine Coburn; Naohiko Ikegaki; David L Kaplan; Bill Chiu Journal: Surgery Date: 2018-07-27 Impact factor: 3.982
Authors: Jordan S Taylor; Burcin Yavuz; Jasmine Zeki; Lauren Wood; Naohiko Ikegaki; Jeannine Coburn; Kristin Harrington; Hiroyuki Shimada; David L Kaplan; Bill Chiu Journal: Surgery Date: 2020-02-28 Impact factor: 3.982
Authors: Xavier M Keutgen; Kimberly J Ornell; Alyx Vogle; Olga Lakiza; Jelani Williams; Paul Miller; Katelyn S Mistretta; Namrata Setia; Ralph R Weichselbaum; Jeannine M Coburn Journal: Ann Surg Oncol Date: 2021-06-05 Impact factor: 5.344
Authors: Kimberly J Ornell; Jordan S Taylor; Jasmine Zeki; Naohiko Ikegaki; Hiroyuki Shimada; Jeannine M Coburn; Bill Chiu Journal: Cancer Med Date: 2020-02-24 Impact factor: 4.452